Corvus Pharmaceuticals (CRVS) Equity Ratio (2022 - 2025)
Historic Equity Ratio for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to 0.89.
- Corvus Pharmaceuticals' Equity Ratio rose 32269.45% to 0.89 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.89, marking a year-over-year increase of 32269.45%. This contributed to the annual value of 0.47 for FY2024, which is 4434.38% down from last year.
- Latest data reveals that Corvus Pharmaceuticals reported Equity Ratio of 0.89 as of Q3 2025, which was up 32269.45% from 0.9 recorded in Q2 2025.
- Corvus Pharmaceuticals' 5-year Equity Ratio high stood at 0.9 for Q2 2025, and its period low was 0.21 during Q3 2024.
- In the last 4 years, Corvus Pharmaceuticals' Equity Ratio had a median value of 0.84 in 2023 and averaged 0.78.
- Per our database at Business Quant, Corvus Pharmaceuticals' Equity Ratio crashed by 7525.59% in 2024 and then soared by 32269.45% in 2025.
- Quarter analysis of 4 years shows Corvus Pharmaceuticals' Equity Ratio stood at 0.82 in 2022, then grew by 3.27% to 0.85 in 2023, then plummeted by 44.34% to 0.47 in 2024, then soared by 88.69% to 0.89 in 2025.
- Its Equity Ratio stands at 0.89 for Q3 2025, versus 0.9 for Q2 2025 and 0.83 for Q1 2025.